Composition for endogenous production of checkpoint protein precursors
AssigneeWyvern Pharmaceuticals Inc.
InventorsJill L. Thompson, Bradley G. Thompson
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for upregulating production and/or functionality of one or more protein precursors of IDO-1, CTLA-4, PD-1, PD-L1, PD-L2 and INF-y. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition whereby the subject's immune system is or is likely to become, dysregulated and where the upregulation of these protein precursors may be of therapeutic benefit.
Claims13
A recombinant virus vector (RVV) comprising a virus with a gene insert coding for a precursor protein of one or more of:
- human cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (SEQ ID NO. 1), programmed cell death protein 1 (PD-1) (SEQ ID NO. 2), programmed death ligand 1 (PD-L1) (SEQ ID NO. 3), programmed death ligand 2 (PD-L2) (SEQ ID NO. 4), indoleamine 2, 3-dioxygenase 1 (IDO-1) (SEQ ID NO. 5), and gamma interferon (INF-γ) (SEQ ID NO. 6).
A recombinant virus vector (RVV) comprising a virus with a gene insert coding a peptide comprising ten or more amino acids in a sequence of:
- SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, and SEQ ID NO. 6.
A method of making an agent/target cell complex, the method comprising a step of administering a recombinant virus vector (RVV) to a target cell for forming the agent/target cell complex, wherein the agent/target cell complex causes the target cell to increase production of a peptide sequence of one or more of:
- SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, and SEQ ID NO. 6.
A pharmaceutical agent comprising:
- a. an agent that upregulates production of one or more of peptide sequences of:
- SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, and SEQ ID NO. 6;
- b. a pharmaceutically acceptable carrier;
- and/or
- c. an excipient.
A method of treating a condition, the method comprising a step of administering to a subject a therapeutically effective amount of an agent for upregulating the subject's production of one or more proteins and/or peptides selected from one or more of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, and SEQ ID NO. 6.
Dependencies are inferred from the claim text.